The Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
Open accessThe DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.
Abstract
Recent clinical guidelines have emphasized the importance of screening for cognitive impairment in older adults with diabetes, however, there is still a lack of understanding about the drug therapy. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are widely used in the treatment of type 2 diabetes and potential applications may include the treatment of obesity as well as the adjunctive treatment of type 1 diabetes mellitus in combination with insulin. Growing evidence suggests that GLP-1 RA has the potential to treat neurodegenerative diseases, particularly in diabetes-related Alzheimer's disease (AD) and Parkinson's disease (PD). Here, we review the molecular mechanisms of the neuroprotective effects of GLP-1 RA in diabetes-related degenerative diseases, including AD and PD, and their potential effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An increase in oxidative stress and ROS production play a role in mitochondrial DNA damage, respiratory impairment, and calcium imbalance, where all these symptoms of mitochondrial dysfunction are associated with AD. 93”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Neurodegeneration and cognitive deterioration can be influenced by the brain’s GLP-1 secretion and its peripheral in those affected by diabetes; however, external GLP-1 treatment may prove advantageous.92,93”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredIn the citing paper
“All GLP-1RAs have been found to cross the blood–brain barrier (BBB) and stimulate GLP-1 receptors in the brain, thus offering neuroprotection [17].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Paladugu, L., Gharaibeh, A., Kolli, N., Learman, C., Hall, T. C., Li, L., Rossignol, J., Maiti, P., & Dunbar, G. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020860 · Cited by 80
RetractedLiraglutide repairs the infarcted heart: The role of the SIRT1/Parkin/mitophagy pathway
Qiao, H., Ren, H., Du, H., Zhang, M., Xiong, X., & Lv, R. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8371 · Cited by 79
RetractedLi, J., Li, N., Yan, S., Lu, Y., Miao, X., Gu, Z., & Shao, Y. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.9946 · Cited by 19
RetractedEndoplasmic Reticulum Stress Links Obesity, Insulin Action, and Type 2 Diabetes
Özcan, U., Cao, Q., Yilmaz, E., Lee, A.-H., Iwakoshi, N. N., Özdelen, E., Tuncman, G., Görgün, C., Glimcher, L. H., & Hotamisligil, G. S. (2004) · Science · doi:10.1126/science.1103160 · Cited by 3,844
Crosstalk of reactive oxygen species and NF-κB signaling
Morgan, M. J., & Liu, Z.-G. (2011) · Cell Research · doi:10.1038/cr.2010.178 · Cited by 3,505
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Urano, F., Wang, X., Bertolotti, A., Zhang, Y., Chung, P., Harding, H. P., & Ron, D. (2000) · Science · doi:10.1126/science.287.5453.664 · Cited by 2,988
Chatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134 · cited 1×
“In AD, Aβ damages microglia, produces inflammatory cytokines and chemokines, and affects surrounding CNS resident cells (astrocytes, oligodendrocytes, and neurons), which may aggravate tau pathology and ultimately lead to neurodegeneration and neuron loss.(166) Inflammation may also be a potential link between diabete…”
BackgroundNew neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory?
Deng, W., Aimone, J. B., & Gage, F. H. (2010) · Nature reviews. Neuroscience · doi:10.1038/nrn2822 · Cited by 2,120 · cited 1×
“The integration of adult-born neurons into the circuitry of the adult hippocampus suggests an important role for adult hippocampal neurogenesis in learning and memory.(103) The insulin/insulin-like growth factor (IGF) pathway promotes NSCs proliferation, differentiation, and survival;(104) therefore, impaired insulin…”
BackgroundNeuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Oxidative Damage Is the Earliest Event in Alzheimer Disease
Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.8.759 · Cited by 1,885
Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums
Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., et al. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.185 · Cited by 1,597
Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications
Biessels, G. J., & Despa, F. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0048-7 · Cited by 1,454
CARLEZONJR, W., DUMAN, R., & NESTLER, E. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.06.005 · Cited by 1,346
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Future uses of GLP-1 may also include the treatment of obesity, as well as the adjunctive treatment of type 1 diabetes mellitus in combination with insulin.(5) Natural GLP-1 degrades within 2–3 min in circulation, thus greatly limiting its effects.”
BackgroundAkt, FoxO and regulation of apoptosis
Zhang, X., Tang, N., Hadden, T. J., & Rishi, A. K. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.03.010 · Cited by 1,103
Adult hippocampal neurogenesis and its role in Alzheimer’s disease
Mu, Y., & Gage, F. H. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-85 · Cited by 1,021
Compromised MAPK signaling in human diseases: an update
Kim, E. K., & Choi, E.-J. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1472-2 · Cited by 1,020
ER stress and the unfolded protein response in neurodegeneration
Hetz, C., & Saxena, S. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.99 · Cited by 1,013
Mitochondrial dysfunction and oxidative stress in Parkinson's disease
Subramaniam, S. R., & Chesselet, M.-F. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.04.004 · Cited by 913
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889
Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms
Kerr, J. S., Adriaanse, B. A., Greig, N. H., Mattson, M. P., Cader, M. Z., Bohr, V. A., & Fang, E. F. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.01.002 · Cited by 870
Kellar, D., & Craft, S. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30231-3 · Cited by 832
Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease
Bejanin, A., Schonhaut, D. R., La Joie, R., Kramer, J. H., Baker, S. L., Sosa, N., Ayakta, N., Cantwell, A., Janabi, M., Lauriola, M., et al. (2017) · Brain · doi:10.1093/brain/awx243 · Cited by 778
Stranahan, A. M., Norman, E. D., Lee, K., Cutler, R. G., Telljohann, R. S., Egan, J. M., & Mattson, M. P. (2008) · Hippocampus · doi:10.1002/hipo.20470 · Cited by 737
Larsen, P. J., Tang-Christensen, M., Holst, J. J., & Ørskov, C. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00434-4 · Cited by 663
GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK
Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., Villarroya, F., Serrano, M., Fernø, J., Salvador, J., Escalada, J., et al. (2014) · Diabetes · doi:10.2337/db14-0302 · Cited by 602 · cited 1×
“GLP-1 RA functions by activating the GLP-1 receptor (GLP-1R), and GLP-1R is widely located throughout the brain.(6,7) The ability of GLP-1 and its agonists to cross the blood–brain barrier suggests its therapeutic potential for NDs.”
BackgroundBCL-2 GENE FAMILY IN THE NERVOUS SYSTEM
Merry, D. E., & Korsmeyer, S. J. (1997) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.20.1.245 · Cited by 588
Insulin in the brain: There and back again
Banks, W. A., Owen, J. B., & Erickson, M. A. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.006 · Cited by 574
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
Takeda, S., Sato, N., Uchio-Yamada, K., Sawada, K., Kunieda, T., Takeuchi, D., Kurinami, H., Shinohara, M., Rakugi, H., & Morishita, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000645107 · Cited by 505
Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504
Verdile, G., Keane, K. N., Cruzat, V. F., Medic, S., Sabale, M., Rowles, J., Wijesekara, N., Martins, R. N., Fraser, P. E., & Newsholme, P. (2015) · Mediators of Inflammation · doi:10.1155/2015/105828 · Cited by 495
The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-β production
Pastorino, L., Sun, A., Lu, P.-J., Zhou, X. Z., Balastik, M., Finn, G., Wulf, G., Lim, J., Li, S.-H., Li, X., et al. (2006) · Nature · doi:10.1038/nature04543 · Cited by 487
Insulin resistance in brain alters dopamine turnover and causes behavioral disorders
Kleinridders, A., Cai, W., Cappellucci, L., Ghazarian, A., Collins, W. R., Vienberg, S. G., Pothos, E. N., & Kahn, C. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500877112 · Cited by 486
Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480
Cork, S. C., Richards, J. E., Holt, M. K., Gribble, F. M., Reimann, F., & Trapp, S. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.07.008 · Cited by 478
Type 2 diabetes and cognitive dysfunction–towards effective management of both comorbidities
Srikanth, V., Sinclair, A. J., Hill-Briggs, F., Moran, C., & Biessels, G. J. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30118-2 · Cited by 465 · cited 1×
“The risk of incident mild cognitive impairment (up to 60%) and dementia (50–100%) is higher in patients with type 2 diabetes than in those without.(2) Recent clinical guidelines have emphasized the importance of screening for cognitive impairment in older adults with diabetes;(3) however, there is still a lack of unde…”
BackgroundInvolvement of Endoplasmic Reticulum Stress in Insulin Resistance and Diabetes
Nakatani, Y., Kaneto, H., Kawamori, D., Yoshiuchi, K., Hatazaki, M., Matsuoka, T.-A., Ozawa, K., Ogawa, S., Hori, M., Yamasaki, Y., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411860200 · Cited by 461
Yusta, B., Baggio, L. L., Estall, J. L., Koehler, J. A., Holland, D. P., Li, H., Pipeleers, D., Ling, Z., & Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.001 · Cited by 446
Obesity-induced endoplasmic reticulum stress causes chronic inflammation in adipose tissue
Kawasaki, N., Asada, R., Saito, A., Kanemoto, S., & Imaizumi, K. (2012) · Scientific Reports · doi:10.1038/srep00799 · Cited by 402
An updated meta-analysis of cohort studies: Diabetes and risk of Alzheimer’s disease
Zhang, J., Chen, C., Hua, S., Liao, H., Wang, M., Xiong, Y., & Cao, F. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.10.024 · Cited by 376
McClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.005 · Cited by 361
Entry of exendin-4 into brain is rapid but may be limited at high doses
Kastin, A. J., & Akerstrom, V (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802206 · Cited by 355
Li, J., Tang, Y., & Cai, D. (2012) · Nature Cell Biology · doi:10.1038/ncb2562 · Cited by 350
Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21483 · Cited by 345
Perluigi, M., Di Domenico, F., & Butterfield, D. A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.014 · Cited by 339
Oxidative toxicity in diabetes and Alzheimer’s disease: mechanisms behind ROS/ RNS generation
Ahmad, W., Ijaz, B., Shabbiri, K., Ahmed, F., & Rehman, S. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0379-z · Cited by 330
Li, Y., Duffy, K. B., Ottinger, M. A., Ray, B., Bailey, J. A., Holloway, H. W., Tweedie, D., Perry, T., Mattson, M. P., Kapogiannis, D., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1314 · Cited by 321
Errant gardeners: glial-cell-dependent synaptic pruning and neurodevelopmental disorders
Neniskyte, U., & Gross, C. T. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.110 · Cited by 313
Cognitive dysfunction in diabetes: how to implement emerging guidelines
Biessels, G. J., & Whitmer, R. A. (2020) · Diabetologia · doi:10.1007/s00125-019-04977-9 · Cited by 310
Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Bassil, F., Fernagut, P.-O., Bezard, E., & Meissner, W. G. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.005 · Cited by 309
Unfolded Protein Response Signaling and Metabolic Diseases
Lee, J., & Ozcan, U. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r113.534743 · Cited by 303
Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Kahan, J., Ell, P., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2014) · Journal of Parkinson's Disease · doi:10.3233/jpd-140364 · Cited by 299
Abbas, T., Faivre, E., & Hölscher, C. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.06.035 · Cited by 282
Skeletal muscle insulin resistance: role of mitochondria and other ROS sources
Di Meo, S., Iossa, S., & Venditti, P. (2017) · Journal of Endocrinology · doi:10.1530/joe-16-0598 · Cited by 282
Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease
Golpich, M., Amini, E., Hemmati, F., Ibrahim, N. M., Rahmani, B., Mohamed, Z., Raymond, A. A., Dargahi, L., Ghasemi, R., & Ahmadiani, A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.03.010 · Cited by 276
Kim, S., Moon, M., & Park, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0132 · Cited by 263
Insulin Resistance and Oxidative Stress in the Brain: What’s New?
Maciejczyk, M., Żebrowska, E., & Chabowski, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040874 · Cited by 262
Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment
Wang, J., Markesbery, W. R., & Lovell, M. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03615.x · Cited by 260
Athauda, D., Gulyani, S., Karnati, H. K., Li, Y., Tweedie, D., Mustapic, M., Chawla, S., Chowdhury, K., Skene, S. S., Greig, N. H., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4304 · Cited by 258
Batista, A. F., Forny‐Germano, L., Clarke, J. R., Lyra e Silva, N. M., Brito‐Moreira, J., Boehnke, S. E., Winterborn, A., Coe, B. C., Lablans, A., Vital, J. F., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5056 · Cited by 246
Diabetes and Risk of Parkinson’s Disease
Cereda, E., Barichella, M., Pedrolli, C., Klersy, C., Cassani, E., Caccialanza, R., & Pezzoli, G. (2011) · Diabetes Care · doi:10.2337/dc11-1584 · Cited by 242
Knight, E. M., Martins, I. V. A., Gümüsgöz, S., Allan, S. M., & Lawrence, C. B. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.02.010 · Cited by 232 · cited 1×
“[3xTgAD]) a high-fat diet may increase the activation of microglia.(168) These studies suggest that diabetes mellitus and a high-fat diet may exacerbate AD inflammation.”
BackgroundEmerging roles of ER stress in the etiology and pathogenesis of Alzheimer's disease
Gerakis, Y., & Hetz, C. (2018) · The FEBS Journal · doi:10.1111/febs.14332 · Cited by 226
The Role of Insulin/IGF-1/PI3K/Akt/GSK3β Signaling in Parkinson's Disease Dementia
Yang, L., Wang, H., Liu, L., & Xie, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00073 · Cited by 226
Kamal, A., Biessels, G. J., Duis, S. E. J., & Gispen, W. H. (2000) · Diabetologia · doi:10.1007/s001250051335 · Cited by 223
Cunha, D. A., Ladrière, L., Ortis, F., Igoillo-Esteve, M., Gurzov, E. N., Lupi, R., Marchetti, P., Eizirik, D. L., & Cnop, M. (2009) · Diabetes · doi:10.2337/db09-0685 · Cited by 221
Targeting endoplasmic reticulum stress in insulin resistance
Salvadó, L., Palomer, X., Barroso, E., & Vázquez-Carrera, M. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.05.007 · Cited by 214
IRE1 signaling exacerbates Alzheimer’s disease pathogenesis
Duran-Aniotz, C., Cornejo, V. H., Espinoza, S., Ardiles, Á. O., Medinas, D. B., Salazar, C., Foley, A., Gajardo, I., Thielen, P., Iwawaki, T., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1694-x · Cited by 213
Femminella, G. D., Frangou, E., Love, S. B., Busza, G., Holmes, C., Ritchie, C., Lawrence, R., McFarlane, B., Tadros, G., Ridha, B. H., et al. (2019) · Trials · doi:10.1186/s13063-019-3259-x · Cited by 213
Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes
Iwai, T., Ito, S., Tanimitsu, K., Udagawa, S., & Oka, J.-I. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.04.008 · Cited by 207 · cited 1×
“First, GLP-1 RA inhibited LPS-induced IL-1β mRNA expression, whereas adenylate cyclase inhibitor preconditioning inhibited this effect, suggesting that cAMP mediated its anti-inflammatory effect.(101) The cAMP/ PKA pathway is also involved in the protection of astrocytes from AGE-induced inflammatory response.”
Mitochondrial dynamics and transport in Alzheimer's disease
Flannery, P. J., & Trushina, E. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.06.009 · Cited by 202
Pipatpiboon, N., Pratchayasakul, W., Chattipakorn, N., & Chattipakorn, S. C. (2012) · Endocrinology · doi:10.1210/en.2011-1502 · Cited by 198
Preproglucagon neurons project widely to autonomic control areas in the mouse brain
Llewellyn-Smith, I. J., Reimann, F., Gribble, F. M., & Trapp, S. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.02.023 · Cited by 194
Ke, Y. D., Delerue, F., Gladbach, A., Götz, J., & Ittner, L. M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007917 · Cited by 190
Salameh, T. S., Rhea, E. M., Talbot, K., & Banks, W. A. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114187 · Cited by 188 · cited 1×
“GLP-1 and its RA cross the blood–brain barrier, with exendin-4 considered as one of the best based on the rate of brain influx, percentage of reaching the brain that accumulates in the brain parenchyma, and percentage of the systemic dose taken per gram of brain tissue.(8) Small amounts of GLP-1 may also be produced b…”
BackgroundAdult neurogenesis in Parkinson’s disease
Marxreiter, F., Regensburger, M., & Winkler, J. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1062-x · Cited by 182
Hippocampal synaptic plasticity and glutamate receptor regulation: influences of diabetes mellitus
Trudeau, F., Gagnon, S., & Massicotte, G. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.055 · Cited by 180
Zhang, L., Zhang, L., Li, L., & Hölscher, C. (2019) · Journal of Parkinson's Disease · doi:10.3233/jpd-181503 · Cited by 173
Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease
Luchsinger, J. A. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.02.048 · Cited by 171 · cited 5×
“Among these mechanisms, brain IR may play a primary role, and it is worth noting that neurologic complications may already occur with prediabetes IR.(12) Oxidative stress,(13) mitochondrial”
BackgroundInfluentialInsulin resistance impairs nigrostriatal dopamine function
Morris, J. K., Bomhoff, G. L., Gorres, B. K., Davis, V. A., Kim, J., Lee, P., Brooks, W. M., Gerhardt, G. A., Geiger, P. C., & Stanford, J. A. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.06.005 · Cited by 167
Drp1-Mediated Mitochondrial Abnormalities Link to Synaptic Injury in Diabetes Model
Huang, S., Wang, Y., Gan, X., Fang, D., Zhong, C., Wu, L., Hu, G., Sosunov, A. A., McKhann, G. M., Yu, H., et al. (2015) · Diabetes · doi:10.2337/db14-0758 · Cited by 165
Neurodegeneration in an animal model of Parkinson’s disease is exacerbated by a high-fat diet
Morris, J. K., Bomhoff, G. L., Stanford, J. A., & Geiger, P. C. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00449.2010 · Cited by 163
Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment
Gejl, M., Brock, B., Egefjord, L., Vang, K., Rungby, J., & Gjedde, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-17718-y · Cited by 163
Laakso, M., Zilinskaite, J., Hansen, T. F., Boesgaard, T. W., Vänttinen, M., Stančáková, A., Jansson, P., Pellmé, F., Holst, J. J., Kuulasmaa, T., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0899-2 · Cited by 158
A Pilot Study of Exenatide Actions in Alzheimer’s Disease
Mullins, R. J., Mustapic, M., Chia, C. W., Carlson, O., Gulyani, S., Tran, J., Li, Y., Mattson, M. P., Resnick, S., Egan, J. M., et al. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190913155950 · Cited by 157
Hsieh, C.-F., Liu, C.-K., Lee, C.-T., Yu, L.-E., & Wang, J.-Y. (2019) · Scientific Reports · doi:10.1038/s41598-018-37215-0 · Cited by 155
Leptin Directly Depolarizes Preproglucagon Neurons in the Nucleus Tractus Solitarius
Hisadome, K., Reimann, F., Gribble, F. M., & Trapp, S. (2010) · Diabetes · doi:10.2337/db10-0128 · Cited by 153
Li, Y., Tweedie, D., Mattson, M. P., Holloway, H. W., & Greig, N. H. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06731.x · Cited by 150
Impairment of hippocampal neurogenesis in streptozotocin-treated diabetic rats
Zhang, W.-J., Tan, Y.-F., Yue, J. T. Y., Vranic, M., & Wojtowicz, J. M. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00928.x · Cited by 149
Porter, D. W., Kerr, B. D., Flatt, P. R., Holscher, C., & Gault, V. A. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01259.x · Cited by 148
Full-length human GLP-1 receptor structure without orthosteric ligands
Wu, F., Yang, L., Hang, K., Laursen, M., Wu, L., Han, G. W., Ren, Q., Roed, N. K., Lin, G., Hanson, M. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14934-5 · Cited by 139
Villalobos-Labra, R., Subiabre, M., Toledo, F., Pardo, F., & Sobrevía, L. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.11.001 · Cited by 137
Qi, L., Ke, L., Liu, X., Liao, L., Ke, S., Liu, X., Wang, Y., Lin, X., Zhou, Y., Wu, L., et al. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.04.052 · Cited by 136
Lee, C., Jeon, S. J., Cho, K. S., Moon, E., Sapkota, A., Jun, H., Ryu, J. H., & Choi, J. W. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0550-2 · Cited by 136
McClean, P. L., Jalewa, J., & Hölscher, C. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.024 · Cited by 135
Neural correlates of liraglutide effects in persons at risk for Alzheimer’s disease
Watson, K. T., Wroolie, T. E., Tong, G., Foland-Ross, L. C., Frangou, S., Singh, M., McIntyre, R. S., Roat-Shumway, S., Myoraku, A., Reiss, A. L., et al. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.08.006 · Cited by 134
Hong, C.-T., Chen, K.-Y., Wang, W., Chiu, J.-Y., Wu, D., Chao, T.-Y., Hu, C.-J., Chau, K.-Y., & Bamodu, O. (2020) · Cells · doi:10.3390/cells9030740 · Cited by 133
Parthsarathy, V., & Hölscher, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058784 · Cited by 130
Chen, J., Xie, J.-J., Shi, K.-S., Gu, Y.-T., Wu, C.-C., Xuan, J., Ren, Y., Chen, L., Wu, Y.-S., Zhang, X.-L., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0217-y · Cited by 130 · cited 1×
“Inhibiting the PI3K/Akt signaling pathway may eliminate the protective effect of GLP-1R by increasing ER stress, suggesting that this pathway may be involved in the effect of GLP-1 on ER stress.(73) Besides, the PKA pathway may also be involved in GLP-1, attenuating the ER stress signaling pathway and protecting cells…”
BackgroundCorsetti, V., Florenzano, F., Atlante, A., Bobba, A., Ciotti, M. T., Natale, F., Della Valle, F., Borreca, A., Manca, A., Meli, G., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv059 · Cited by 129
Hölscher, C. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.009 · Cited by 127
GLP-1’s role in neuroprotection: a systematic review
Erbil, D., Eren, C. Y., Demirel, C., Küçüker, M. U., Solaroğlu, I., & Eser, H. Y. (2019) · Brain Injury · doi:10.1080/02699052.2019.1587000 · Cited by 126
Wang, X., Zhai, Y., Xu, L., Qiao, C., Sun, X., Ding, J., Lu, M., & Hu, G. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.11.001 · Cited by 121
Chabot, C., Massicotte, G., Milot, M., Trudeau, F., & Gagné, J. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00648-3 · Cited by 120
Feng, P., Zhang, X., Li, D., Ji, C., Yuan, Z., Wang, R., Xue, G., Li, G., & Hölscher, C. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.012 · Cited by 120
Parthsarathy, V., & Hölscher, C. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.12.012 · Cited by 119
Role of Immunity and Inflammation in the Pathophysiology of Neurodegenerative Diseases
Fakhoury, M. (2015) · Neurodegenerative Diseases · doi:10.1159/000369933 · Cited by 118
Moreira, P. I., Santos, M. S., Moreno, A. M., Seiça, R., & Oliveira, C. R. (2003) · Diabetes · doi:10.2337/diabetes.52.6.1449 · Cited by 117
Gilman, C. P., Perry, T., Furukawa, K., Grieg, N. H., Egan, J. M., & Mattson, M. P. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02073.x · Cited by 114
Neuronal failure in Alzheimer’s disease: a view through the oxidative stress looking-glass
Bonda, D. J., Wang, X., Lee, H.-G., Smith, M. A., Perry, G., & Zhu, X. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1424-x · Cited by 114
A New Alzheimers Disease Interventive Strategy: GLP-1
Perry, T., & Greig, N. (2004) · Current Drug Targets · doi:10.2174/1389450043345245 · Cited by 112
Costa, C. A. D., Manaa, W. E., Duplan, E., & Checler, F. (2020) · Cells · doi:10.3390/cells9112495 · Cited by 110
Cai, H.-Y., Yang, J.-T., Wang, Z.-J., Zhang, J., Yang, W., Wu, M.-N., & Qi, J.-S. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.114 · Cited by 108
Cai, H.-Y., Hölscher, C., Yue, X.-H., Zhang, S., Wang, X.-H., Qiao, F., Yang, W., & Qi, J. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.02.022 · Cited by 107
GLP-1 secretion by microglial cells and decreased CNS expression in obesity
Kappe, C., Tracy, L. M., Patrone, C., Iverfeldt, K., & Sjöholm, Å. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-276 · Cited by 107
Glucagon-like peptide-1 suppresses neuroinflammation and improves neural structure
Yoon, G., Kim, Y.-K., & Song, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104615 · Cited by 107
Jayaraj, R. L., Azimullah, S., & Beiram, R. (2020) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2019.12.028 · Cited by 107
Ma, T., Du, X., Pick, J. E., Sui, G., Brownlee, M., & Klann, E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2107-12.2012 · Cited by 104
Hansen, H. H., Barkholt, P., Fabricius, K., Jelsing, J., Terwel, D., Pyke, C., Knudsen, L. B., & Vrang, N. (2015) · Brain Research · doi:10.1016/j.brainres.2015.12.052 · Cited by 102
GLP-1a: Going beyond Traditional Use
Laurindo, L. F., Barbalho, S. M., Guiguer, E. L., da Silva Soares de Souza, M., de Souza, G. A., Fidalgo, T. M., Araújo, A. C., de Souza Gonzaga, H. F., de Bortoli Teixeira, D., de Oliveira Silva Ullmann, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020739 · Cited by 102
Chen, S., Sun, J., Zhao, G., Guo, A. W., Chen, Y., Fu, R., & Deng, Y. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2250-8 · Cited by 100
Impaired neurogenesis in adult type-2 diabetic rats
Lang, B. T., Yan, Y., Dempsey, R. J., & Vemuganti, R. (2009) · Brain Research · doi:10.1016/j.brainres.2008.12.026 · Cited by 98
Dysregulation of parkin in the substantia nigra of db/db and high-fat diet mice
Khang, R., Park, C., & Shin, J.-H. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.03.017 · Cited by 97
Solmaz, V., Çınar, B. P., Yiğittürk, G., Çavuşoğlu, T., Taşkıran, D., & Erbaş, O. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.09.024 · Cited by 96
Yang, Y., Zhang, J., Ma, D., Zhang, M., Hu, S., Shao, S., & Gong, C.-X. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130491 · Cited by 91
Egefjord, L., Gejl, M., Møller, A., Brændgaard, H., Gottrup, H., Antropova, O., Møller, N., Poulsen, H. E., GJEDDE, A. H., Brock, B., et al. (2012) · PubMed · Cited by 91
Xiong, H., Zheng, C., Wang, J., Song, J., Zhao, G., Shen, H., & Deng, Y. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-130584 · Cited by 90
Duarte, A. I., Candeias, E., Alves, I. N., Mena, D., Silva, D. F., Machado, N. J., Campos, E. J., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051746 · Cited by 90
Xu, W., Yang, Y., Yuan, G., Zhu, W., Ma, D., & Hu, S. (2015) · Journal of Investigative Medicine · doi:10.1097/jim.0000000000000129 · Cited by 89
Zheng, X., Xu, F., Liang, H., Cao, H., Cai, M., Xu, W., & Weng, J. (2017) · Hepatology · doi:10.1002/hep.29238 · Cited by 85
Fauconnier, J., Lanner, J. T., Zhang, S.-J., Tavi, P., Bruton, J. D., Katz, A., & Westerblad, H. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2375 · Cited by 82
Holubová, M., Hrubá, L., Popelová, A., Bencze, M., Pražienková, V., Gengler, S., Kratochvílová, H., Haluzík, M., Železná, B., Kuneš, J., et al. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.11.002 · Cited by 82
de la Monte, S. M., Re, E., Longato, L., & Tong, M. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-111728 · Cited by 81
Hippocampal Neuropathology of Diabetes Mellitus is Relieved by Estrogen Treatment
Saravia, F., Beauquis, J., Revsin, Y., Homo‐Delarche, F., de Kloet, E. R., & Nicola, A. F. D. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9096-y · Cited by 79
Porter, W. D., Flatt, P. R., Hölscher, C., & Gault, V. A. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.91 · Cited by 79
Wang, Z., Huang, Y., Cheng, Y. H., Tan, Y., Wu, F., Wu, J., Shi, H., Zhang, H., Yu, X., Gao, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12925 · Cited by 79
IRS-2 Deficiency Impairs NMDA Receptor-Dependent Long-term Potentiation
Martín, E. D., Sánchez-Perez, A., Trejo, J. L., Martin-Aldana, J. A., Cano Jaimez, M., Pons, S., Acosta Umanzor, C., Menes, L., White, M. F., & Burks, D. J. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhr216 · Cited by 78
Zhang, X., Zhang, Z., Zhao, Y., Jiang, N., Qiu, J., Yang, Y., Li, J., Liang, X., Wang, X., Tse, G., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005945 · Cited by 78
An, J., Zhou, Y., Zhang, M., Xie, Y., Ke, S., Liu, L., Pan, X., & Chen, Z. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.111932 · Cited by 78
Rieusset, J. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.02.006 · Cited by 77
What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson’s Disease: A Post Hoc Analysis
Athauda, D., Maclagan, K., Budnik, N., Zampedri, L., Hibbert, S., Skene, S. S., Chowdhury, K., Aviles-Olmos, I., Limousin, P., & Foltynie, T. (2018) · Journal of Parkinson's Disease · doi:10.3233/jpd-181329 · Cited by 77
Post hoc analysis of the Exenatide‐ PD trial—Factors that predict response
Athauda, D., Maclagan, K., Budnik, N., Zampedri, L., Hibbert, S., Aviles‐Olmos, I., Chowdhury, K., Skene, S. S., Limousin, P., & Foltynie, T. (2019) · European Journal of Neuroscience · doi:10.1111/ejn.14096 · Cited by 77
Su, C., Shen, Z., Cui, R.-X., Huang, Y., Xu, D., Zhao, F., Pan, J., Shi, A.-M., Liu, T., & Yu, Y. (2020) · Neuroscience Bulletin · doi:10.1007/s12264-019-00459-5 · Cited by 77
Oishi, K., Watatani, K., Itoh, Y., Okano, H., Guillemot, F., Nakajima, K., & Gotoh, Y. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808400106 · Cited by 75
Garabadu, D., & Verma, J. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.04.006 · Cited by 75
Nisticò, R., Cavallucci, V., Piccinin, S., Macrì, S., Pignatelli, M., Mehdawy, B., Blandini, F., Laviola, G., Lauro, D., Mercuri, N. B., et al. (2012) · NeuroMolecular Medicine · doi:10.1007/s12017-012-8184-z · Cited by 73
Huang, H.-J., Chen, Y.-H., Liang, K.-C., Jheng, Y.-S., Jhao, J.-J., Su, M.-T., Lee-Chen, G.-J., & Hsieh-Li, H. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039656 · Cited by 72
Role of Mitochondrial Stress Protein HSP60 in Diabetes-Induced Neuroinflammation
Liyanagamage, D. S. N. K., & Martinus, R. D. (2020) · Mediators of Inflammation · doi:10.1155/2020/8073516 · Cited by 72
Ma, D., Chen, F., Xu, W., Yue, W., Yuan, G., & Yang, Y. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13248 · Cited by 69
GLP-1 receptor agonists for Parkinson's disease
Mulvaney, C. A., Duarte, G. S., Handley, J., Evans, D. J., Menon, S., Wyse, R., & Emsley, H. C. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012990.pub2 · Cited by 69
Bomba, M., Granzotto, A., Castelli, V., ONOFRJ, M. C., Lattanzio, R., Cimini, A., & Sensi, S. L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-190237 · Cited by 69
Chen, S., An, F.-M., Yin, L., Liu, A.-R., Yin, D.-K., Yao, W.-B., & Gao, X.-D. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.10.038 · Cited by 68
Esmaeili, M. H., Enayati, M., Khabbaz, F., Ebrahimian, F., & Salari, A. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112359 · Cited by 63
Yan, W., Pang, M., Yu, Y., Gou, X., Si, P., Zhawatibai, A., Zhang, Y., Zhang, M., Guo, T., Yi, X., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116566 · Cited by 62
Panagaki, T., Michael, M., & Hölscher, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-16488-x · Cited by 61
Cheng, C. K., Luo, J., Lau, C. W., Cho, W. C. S., Ng, C., Ronald, C. W., Tian, X. Y., & Huang, Y. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00589-x · Cited by 61
Wang, S.-H., Sun, Z.-L., Guo, Y.-J., Yuan, Y., & Yang, B.-Q. (2009) · Toxicological Sciences · doi:10.1093/toxsci/kfp126 · Cited by 60
Bao, Y., Jiang, L., Chen, H., Zou, J., Liu, Z., & Shi, Y. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000430199 · Cited by 60
Cheng, H., Gang, X., Liu, Y., Wang, G., Zhao, X., & Wang, G. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00179.2019 · Cited by 60
Self-citationJantrapirom, S., Nimlamool, W., Chattipakorn, N., Chattipakorn, S., Temviriyanukul, P., Inthachat, W., Govitrapong, P., & Potikanond, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051725 · Cited by 60
An, F.-M., Chen, S., Xu, Z., Yin, L., Wang, Y., Liu, A.-R., Yao, W.-B., & Gao, X.-D. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.023 · Cited by 59
Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of α-Synucleinopathy
Bu, L.-L., Liu, Y., Shen, Y., Fan, Y., Yu, W., Jiang, D., Tang, Y., Yang, Y., Wu, P., Zuo, C., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01018-5 · Cited by 59
Hou, J., Manaenko, A., Hakon, J., Hansen-Schwartz, J., Tang, J., & Zhang, J. H. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.133 · Cited by 57
Depletion of Caveolin-1 in Type 2 Diabetes Model Induces Alzheimer's Disease Pathology Precursors
Bonds, J. A., Shetti, A., Bheri, A., Chen, Z., Disouky, A., Tai, L. M., Mao, M., Head, B. P., Bonini, M. G., Haus, J. M., et al. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.0730-19.2019 · Cited by 57
Stress, the Endoplasmic Reticulum, and Insulin Resistance
TSIOTRA, P. C., & TSIGOS, C. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1367.007 · Cited by 56
Valastro, B., Cossette, J., Lavoie, N., Gagnon, S., Trudeau, F., & Massicotte, G. (2002) · Diabetologia · doi:10.1007/s00125-002-0818-5 · Cited by 55
Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Diabetes
Rocha, M., Díaz‐Morales, N., Rovira‐Llopis, S., Escribano‐López, I., Bañuls, C., Hernández‐Mijares, A., Diamanti‐Kandarakis, E., & Víctor, V. M. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160209152033 · Cited by 55
Neuroprotective Effects of Eexenatide in a Rotenone-Induced Rat Model of Parkinson’s Disease
Aksoy, D., Solmaz, V., Çavuşoğlu, T., Meral, A., Ateş, U., & Erbaş, O. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.05.002 · Cited by 55
Prion Protein Helix1 Promotes Aggregation but Is Not Converted into beta-Sheet
Watzlawik, J. O., Skóra, L., Frense, D., Griesinger, C., Zweckstetter, M., Schulz‐Schaeffer, W., & Kramer, M. L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605141200 · Cited by 55
Elbassuoni, E. A., & Ahmed, R. F. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104583 · Cited by 54
Carranza-Naval, M. J., del Marco, A., Hierro-Bujalance, C., Alves-Martinez, P., Infante-Garcia, C., Vargas-Soria, M., Herrera, M., Barba-Cordoba, B., Atienza-Navarro, I., Lubian-Lopez, S., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.741923 · Cited by 54
Morales, P. E., Torres, G., Sotomayor-Flores, C., Peña‐Oyarzún, D., Rivera-Mejías, P., Paredes, F., & Chiong, M. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.03.004 · Cited by 53
Seppa, K., Toots, M., Reimets, R., Jagomäe, T., Koppel, T., Pallase, M., Hasselholt, S., Krogsbæk Mikkelsen, M., Randel Nyengaard, J., Vasar, E., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52295-2 · Cited by 53
Ohtake, N., Saito, M., Eto, M., & Seki, K. (2014) · Regulatory Peptides · doi:10.1016/j.regpep.2014.04.003 · Cited by 52
Bonds, J. A., Shetti, A., Stephen, T. K. L., Bonini, M. G., Minshall, R. D., & Lazarov, O. (2020) · Scientific Reports · doi:10.1038/s41598-020-73401-9 · Cited by 52
Exendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway
Wang, M., Huang, Y., Zhang, G.-P., Mao, L., Xia, Y., Mei, Y.-W., & Hu, B. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.025 · Cited by 51
Toots, M., Seppa, K., Jagomäe, T., Koppel, T., Pallase, M., Heinla, I., Terasmaa, A., Plaas, M., & Vasar, E. (2018) · Scientific Reports · doi:10.1038/s41598-018-28314-z · Cited by 51
Luciani, P., Deledda, C., Benvenuti, S., Cellai, I., Squecco, R., Monici, M., Cialdai, F., Luciani, G., Danza, G., Stefano, C. D., et al. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0398-3 · Cited by 50
Lin, T.-K., Lin, K.-J., Lin, H.-Y., Lin, K.-L., Lan, M.-Y., Wang, P.-W., Wang, T.-J., Wang, F.-S., Tsai, P.-C., Liou, C.-W., et al. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.697440 · Cited by 49
Chang, G., Liu, J., Qin, S., Jiang, Y., Zhang, P., Yu, H., Lu, K., Zhang, N., Cao, L., Wang, Y., et al. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3318 · Cited by 48
Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice
Lennox, R., Flatt, P. R., & Gault, V. A. (2014) · Peptides · doi:10.1016/j.peptides.2014.08.014 · Cited by 47 · cited 2×
“In a GLP-1R knockout mouse model, LTP in the CA1 area of the hippocampus was severely impaired.142 In addition, GLP-1 RA upregulated neurotrophic tyrosine kinase receptor type 2 and mTOR genes in the hippocampus of high-fat-fed mice, which are involved in regulating synaptic plasticity and LTP.143 By modulating calciu…”
BackgroundZhang, Y., Xie, J., Xu, X., Hu, J., Xu, T., Jin, S., Yang, S., & Wang, J. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-018-00336-7 · Cited by 47
Self-citationEndoplasmic Reticulum Stress Impairs Insulin Receptor Signaling in the Brains of Obese Rats
Liang, L., Chen, J., Zhan, L., Lu, X., Sun, X., Sui, H. X., Zheng, L., Xiang, H., & Zhang, F.-L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126384 · Cited by 45
Giuntini, M., Baldacci, F., Prete, E. D., Bonuccelli, U., & Ceravolo, R. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.02.016 · Cited by 44
Diabetes onset influences hippocampal synaptic plasticity in streptozotocin-treated rats
Sasaki‐Hamada, S., Sacai, H., & Oka, J.-I. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.081 · Cited by 43
Zhong, Y., Zhu, Y., He, T., Li, W., Yan, H., & Miao, Y. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.09.023 · Cited by 42
Effect of exercise on type 2 diabetes-associated cognitive impairment in rats
Mehta, B. K., Singh, K., & Banerjee, S. (2018) · International Journal of Neuroscience · doi:10.1080/00207454.2018.1526795 · Cited by 42
Evaluation of neuroprotective effect of glucagon‐like peptide 1 analogs using neuroimaging
Femminella, G. D., & Edison, P. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.012 · Cited by 41
He, J., Wang, C., Sun, Y., Lu, B., Cui, J., Dong, N., Zhang, M., LIU, Y., & Yu, B. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2509 · Cited by 41
Peripheral Levels of AGEs and Astrocyte Alterations in the Hippocampus of STZ-Diabetic Rats
Nardin, P., Zanotto, C., Hansen, F., Batassini, C., Gasparin, M. S., Sesterheim, P., & Gonçalves, C. (2016) · Neurochemical Research · doi:10.1007/s11064-016-1912-2 · Cited by 40
Nutrient control of neural stem cells
Spéder, P., Liu, J., & Brand, A. H. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.08.004 · Cited by 39
Gibson, G. E., & Thakkar, A. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2182-3 · Cited by 39
Sharma, S., & Taliyan, R. (2018) · Behavioural Brain Research · doi:10.1016/j.bbr.2018.05.025 · Cited by 38
Diz-Chaves, Y., Toba, L., Fandiño, J., González-Matías, L. C., Garcia-Segura, L. M., & Mallo, F. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1370-7 · Cited by 38
Yang, X. Q., Chen, Y., Zhang, W., Zhang, Z., Yang, X., Wang, P., & Yuan, H. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s271160 · Cited by 38
Qi, L., Chen, Z., Wang, Y., Liu, X., Liu, X., Ke, L., Zheng, Z., Lin, X., Zhou, Y., Liu, L., et al. (2017) · Europe PMC (PubMed Central) · Cited by 37
Antidiabetic Agents for Treatment of Parkinson’s Disease: A Meta-Analysis
Wang, S.-Y., Wu, S.-L., Chen, T.-C., & Chuang, C.-S. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17134805 · Cited by 37
Research works printed but not linked: 3
- Youssef, 2009, West Indian Med J, 58, 410
- Qi, 2017, Am J Transl Res, 9, 247
- Egefjord, 2012, Dan Med J, 59, A4519
Cited by
Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317
“GLP-1 therapy decreased IL-1b mRNA production compared to the LPS alonetreated cultures (67, 72).”
BackgroundMetabolic memory: mechanisms and diseases
Dong, H., Sun, Y., Nie, L., Cui, A., Zhao, P., Leung, W. K., & Wang, Q. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01755-x · Cited by 213
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes
Monney, M., Jornayvaz, F. R., & Gariani, K. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101470 · Cited by 91
Metadata
- Authors
- Cheng, D., Yang, S., Zhao, X., & Wang, G.
- Affiliations
- First Hospital of Jilin University (CN)
- Corresponding author
- Wang, Guixia
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2022-03
- Volume
- Volume 16
- Pages
- 665-684
- ISSN
- 1177-8881 (ISSN-L)
- PMC
- PMC8943601
- OpenAlex
- W4221041575
- Cited by
- 84
- References
- 229
- Citations by year
- 2026: 21 · 2025: 27 · 2024: 13 · 2023: 18 · 2022: 5
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Drug Design Development and Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- People's Government of Jilin Province
- Jilin University
- First Hospital of Jilin University
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- GLP-1 receptor agonists, neurodegenerative diseases, diabetes mellitus, Alzheimer's disease, Parkinson's disease, neuroprotection, type 2 diabetes, type 1 diabetes, obesity, cognitive impairment, molecular mechanisms
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Aged, Diabetes Mellitus, Type 2, Humans, Insulin, Neurodegenerative Diseases, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.